Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0393645 | 0.415249 | 0.5 |
Schistosoma mansoni | DNA topoisomerase type I | 0.0772932 | 1 | 1 |
Leishmania major | DNA topoisomerase IB, large subunit | 0.0772932 | 1 | 1 |
Echinococcus granulosus | DNA topoisomerase 1 | 0.0772932 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0363833 | 0.369287 | 0.235005 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.0337011 | 0.327935 | 0.327935 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0470858 | 0.534289 | 0.261612 |
Loa Loa (eye worm) | carboxylesterase | 0.0363833 | 0.369287 | 0.235005 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.0337011 | 0.327935 | 1 |
Plasmodium vivax | topoisomerase I, putative | 0.0772932 | 1 | 1 |
Plasmodium falciparum | telomerase reverse transcriptase | 0.0722265 | 0.921887 | 0.921887 |
Brugia malayi | DNA topoisomerase I | 0.0772932 | 1 | 1 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0581027 | 0.704138 | 0.641148 |
Plasmodium falciparum | topoisomerase I | 0.0772932 | 1 | 1 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.0581027 | 0.704138 | 0.530909 |
Loa Loa (eye worm) | hypothetical protein | 0.039419 | 0.416089 | 0.291772 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0581027 | 0.704138 | 0.704138 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0581027 | 0.704138 | 0.530909 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.0337011 | 0.327935 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.039419 | 0.416089 | 0.291772 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0581027 | 0.704138 | 0.5 |
Giardia lamblia | DNA topoisomerase II | 0.055092 | 0.657722 | 0.5 |
Mycobacterium leprae | Probable DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) | 0.0150175 | 0.0398867 | 0.5 |
Trypanosoma brucei | DNA topoisomerase ii | 0.0648696 | 0.808464 | 0.44311 |
Plasmodium vivax | telomerase reverse transcriptase, putative | 0.0722265 | 0.921887 | 0.921887 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0363833 | 0.369287 | 0.235005 |
Loa Loa (eye worm) | DNA topoisomerase I | 0.0772932 | 1 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0393645 | 0.415249 | 0.5 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0581027 | 0.704138 | 0.704138 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0581027 | 0.704138 | 0.530909 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0393645 | 0.415249 | 0.5 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0337011 | 0.327935 | 0.327935 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0337011 | 0.327935 | 1 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0581027 | 0.704138 | 0.704138 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0581027 | 0.704138 | 0.530909 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0581027 | 0.704138 | 0.5 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0470858 | 0.534289 | 0.261612 |
Echinococcus multilocularis | DNA topoisomerase 1 | 0.0772932 | 1 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0470858 | 0.534289 | 0.261612 |
Toxoplasma gondii | DNA topoisomerase I, putative | 0.0772932 | 1 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0648696 | 0.808464 | 0.44311 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0470858 | 0.534289 | 0.261612 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0470858 | 0.534289 | 0.261612 |
Brugia malayi | Probable DNA topoisomerase II | 0.0581027 | 0.704138 | 0.530909 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0648696 | 0.808464 | 0.44311 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.0337011 | 0.327935 | 1 |
Schistosoma mansoni | DNA topoisomerase type I | 0.0772932 | 1 | 1 |
Trypanosoma cruzi | DNA topoisomerase IB, large subunit, putative | 0.0772932 | 1 | 1 |
Plasmodium falciparum | DNA gyrase subunit B | 0.0337011 | 0.327935 | 0.327935 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0470858 | 0.534289 | 0.261612 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0269342 | 0.223609 | 0.681869 |
Schistosoma mansoni | DNA topoisomerase type I | 0.0772932 | 1 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.0470858 | 0.534289 | 0.261612 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.0337011 | 0.327935 | 1 |
Trypanosoma brucei | DNA topoisomerase IB, large subunit | 0.0772932 | 1 | 1 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.0648696 | 0.808464 | 0.44311 |
Schistosoma mansoni | P2X receptor subunit | 0.0470858 | 0.534289 | 0.261612 |
Schistosoma mansoni | P2X receptor subunit | 0.0470858 | 0.534289 | 0.261612 |
Loa Loa (eye worm) | hypothetical protein | 0.0363833 | 0.369287 | 0.235005 |
Schistosoma mansoni | DNA topoisomerase II | 0.0581027 | 0.704138 | 0.530909 |
Schistosoma mansoni | P2X receptor subunit | 0.0470858 | 0.534289 | 0.261612 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 4.5 uM | Antimalarial activity against erythrocytic stage of chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 assessed as inhibition of [3H]-hypoxanthine incorporation incubated for 48 hrs prior to [3H]-hypoxanthine addition measured after 24 hrs by liquid scintillation counting | ChEMBL. | 23517371 |
PB (ADMET) | = 93.7 % | Binding affinity to human albumin by HPLC analysis relative to control | ChEMBL. | 23517371 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | 23517371 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.